-73%

est. 2Y upside i

HealthcareSeries B

Rank

#3524

Sector

Medical Technology

Est. Liquidity

~5Y

Data Quality

Data: Low

Axio faces significant headwinds with declining revenue and a stale valuation.

Last updated: July 19, 2026

Bull (15%)-30%

If Axio achieves new FDA clearances and enters high-growth segments like veterinary, exit multiple could hold at 5x declining revenue, but 20% dilution erodes returns; raw upside -10% minus dilution yields -30%.

Base (50%)-66%

Continued revenue decline of -17% leads to exit multiple compression to 3x, yielding raw -46% upside; after 20% dilution, net -66%.

Bear (35%)-100%

Exit value below $20.5M preference stack results in common stock recovery of -100% per preference liquidation override.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

56900%

Total preferred liquidation preference of $20.5M exceeds the estimated entry valuation of $15M, meaning common stock is out of the money.

Dilution Risk

high

No recent funding suggests need for capital raise, likely 20% dilution for employees.

Secondary Liquidity

none

No secondary market activity reported; liquidity event uncertain.

Questions to Ask at the Interview

Strategic questions based on Axio's data — designed to show you've done your homework.

  • 1

    “How does Axio plan to reverse its revenue decline and regain growth traction?”

  • 2

    “Given the 4+ years since the last round, what is the current burn rate and cash runway?”

  • 3

    “What is the company's strategy for a liquidity event (acquisition or IPO) and how does it align with employee equity?”

Community

Valuation Sentiment

Our model estimates -73% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.